Phaseline

Companies › Forte Biosciences

Forte Biosciences: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Gastroenterology, Immunology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FB102
JAK inhibitor
–Phase 2Celiac Disease; Vitiligo; Healthy Volunteer; Alopecia AreataDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06905873FB102Phase 1VitiligoImmunologyDec 2026
NCT07623057FB102Phase 1Healthy VolunteerOtherFeb 2027
NCT06982963FB102Phase 2Celiac DiseaseGastroenterologyFeb 2027
NCT07205159FB102Phase 1Alopecia AreataImmunologyMar 2027

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zealand Pharma LyGenesis Mikrobiomik Healthcare Company Bluefin Biomedicine Tego Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.